Neoantigen-primed DC Vaccines Therapy for Refractory Lung Cancer

Summary

Various of immunotherapies are now widely applied in the treatment of lung cancer. Neoantigens arising from the mutations of the tumor genome expressed specifically on the tumor cell instead of normal cells, suggesting that vaccines targeting neoantigens should generate a highly tumor-specific response with minimal off-target effects. Neoantigens are highly suitable for the development of cancer vaccines. The study aims to evaluate the safety and efficacy of neoantigen-loaded dendritic cell (DC) vaccines for refractory lung cancer.

Timeline

Start

2019-04-01

Primary completion

2020-06-30

Completion

2020-12-30

Drugs

Indications